CHM Cannabis
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, $Pistol Pete$
Search This Board: 
Last Post: 12/13/2018 2:55:46 PM - Followers: 417 - Board type: Free - Posts Today: 0


     WEEKLY NUMBERS     http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116919069
Many Afrezza users have reported rapid drops in A1c

Yeah, but in the only clinical trials that compared Afrezza to rapid acting insulins, Afrezza did no such thing.

Straight from the label:

Absolute HgA1c reduction:
Afrezza : 0.21
Rapid I : 0.40

% of patients reducing by 7% or more:
Affreza: 13.8%
Rapid I: 27.1%

And there is your problem. Tweets do not counter clinical trial data.

Afrezza avoids the needle, for sure.But is it better?

It has a faster/narrower spike. BUT, to take advantage of this, the user need to know how to use it.

Perhaps a few users have got it down, and do better. But that does not work for the masses.

MNKD really needs to figure out how to work with the new electronic glucose monitors to solve this issue.        

 p.s. Reading the Mannkind report at FDA.GOV provides plenty of clues why Afrezza is a failure.


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at: http://www.mannkindcorp.com/about-us-overview.htm#sthash.6MYBImtD.dpuf


Alfred E. Mann, Founder (Deceased)

Alfred E. Mann had been one of MNKD's directors since April 1999, Chairman of the Board since December 2001 and  Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio 

Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge


http://www.mnkd.proboards.com/  A good forum for discussion on Mankind


MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.





CHM Cannabis
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MNKD News: Current Report Filing (8-k) 12/03/2018 04:07:39 PM
MNKD News: Confidential Treatment Order (ct Order) 11/30/2018 11:16:42 AM
MNKD News: MannKind Appoints Christine Mundkur to its Board of Directors 11/27/2018 09:00:00 AM
MNKD News: Statement of Changes in Beneficial Ownership (4) 11/15/2018 06:13:16 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 11/15/2018 06:11:12 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#30134  Sticky Note $MNKD Early Insulin Therapy for Type 2 testing $Pistol Pete$ 09/03/18 12:26:56 PM
#27521  Sticky Note From the MNKD proboards -->> TTIME 02/14/18 02:49:38 PM
#31225   Yeah, it's blasting off in the wrong direction! LOL SidVicious 12/13/18 02:55:46 PM
#31224   https://finance.yahoo.com/news/mnkd-zacks-scr-initiates-coverage-150000565.html? STOCKSEEK 12/12/18 05:41:52 PM
#31223   Yeah, it's going to blast off like you SidVicious 12/11/18 02:29:02 AM
#31222   CLAY TRADER will post SOON....if that happens in Go4itbigtime 12/10/18 11:25:33 AM
#31221   Sid: Can't you just feel it that MNKD's Go4itbigtime 12/10/18 11:21:20 AM
#31220   Please, any "improvement" was just due to the parkourstar 12/09/18 10:48:57 AM
#31219   Well scrips finally making a nice move almost Hypi 12/07/18 01:28:31 PM
#31218   No, right now MNKD needs UTHR to say parkourstar 12/06/18 09:40:08 PM
#31217   MANKIND NEEDS COMPASSION!!! THE LOG 12/03/18 01:53:35 PM
#31216   Forgot to add only 3 days...really probably only TTIME 12/02/18 11:05:15 PM
#31215   Close? RLS is at least four years parkourstar 12/02/18 09:18:21 PM
#31214   Too hilarious! Afrezzaguy doesn't tweet anything since parkourstar 12/02/18 09:13:29 PM
#31213   "NEW SCRIPT NUMBERS: parkourstar 12/02/18 09:06:56 PM
#31212   https://twitter.com/Afrezzaguy TTIME 12/02/18 06:36:54 PM
#31211   Agree everything way to quiet and there is Hypi 12/01/18 07:34:28 PM
#31210   Wonder what's the TrX and NrX count for lakingsphan0427 11/30/18 04:21:13 PM
#31205   Looks like short interest is stuck here to Profit 11/27/18 07:08:05 PM
#31204   No need to. The stock is stuck where SidVicious 11/27/18 01:19:20 PM
#31203   Sid: Big things are coming...$3 before $1.40...want to bet? Go4itbigtime 11/27/18 10:25:49 AM
#31199   Get their ducks all lined up for some Go4itbigtime 11/27/18 09:47:06 AM
#31198   thank you, Mannkind Corp. (MNKD) mick 11/25/18 07:37:01 PM
#31197   "NEW SCRIPT NUMBERS: parkourstar 11/23/18 09:54:21 AM
#31196   Get ready for this to get back to SidVicious 11/21/18 01:16:48 PM
#31195   Sid: Get ready for it... Go4itbigtime 11/21/18 11:35:15 AM
#31194   "NEW SCRIPT NUMBERS: parkourstar 11/16/18 09:02:52 AM
#31193   Two dollars is nothing...think $5 or better Go4itbigtime 11/15/18 11:56:05 PM
#31192   Like a move to $2? SidVicious 11/15/18 11:15:05 PM
#31191   "Today's deal between ARNA and UTHR kind of parkourstar 11/15/18 11:14:26 PM
#31190   Good things coming imo Go4itbigtime 11/15/18 10:18:21 PM
#31189   Confidence is High! Profit 11/15/18 08:29:41 PM
#31188   They bought their shares awhile back Go4itbigtime 11/15/18 08:09:09 PM
#31187   I don't think so. They are not Aloha96707 11/15/18 07:30:33 PM
#31186   I agree Go4itbigtime 11/15/18 07:04:43 PM
#31185   With 4 insiders buys today something is about lakingsphan0427 11/15/18 06:28:03 PM
#31184   Seems we can't break out of this level. Moby Dick 11/12/18 10:15:18 AM
#31183   Yeah, I hear their negotiating with Tinker Bell parkourstar 11/09/18 10:33:34 AM
#31182   "NEW SCRIPT NUMBERS: parkourstar 11/09/18 09:13:49 AM
#31181   Gotta believe they have several things they are Go4itbigtime 11/08/18 10:52:07 AM
#31180   Oral or Sub-Lingual delivery of drugs and supplements XenaLives 11/07/18 01:39:58 PM
#31179   "What I think one should at least WONDER parkourstar 11/07/18 12:06:45 PM
#31178   Spencer Osborne thinks MNKD should dump afrezza: parkourstar 11/07/18 12:04:25 PM
#31175   Not good. As usual. SidVicious 11/06/18 10:33:27 AM
#31174   What were the numbers last Friday..anybody? Go4itbigtime 11/06/18 10:13:50 AM
#31173   Still under 2. Hanging around 1.80. Even with SidVicious 11/05/18 05:16:42 PM
#31172   Wow, one and a half million shares traded. parkourstar 11/05/18 04:06:32 PM
#31171   yeah but not the time frame you thought. SidVicious 11/02/18 12:54:48 PM
#31170   Sid..past 11:00..no play..you had your chance Go4itbigtime 11/02/18 11:03:43 AM
#31169   Yeah, waiting to see how badly tax loss parkourstar 11/02/18 10:15:06 AM
#31168   Apparently not today, though -- down 15 cents parkourstar 11/02/18 10:14:01 AM
#31167   So it seems, the numbers posted for last parkourstar 11/02/18 10:12:17 AM